The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
There is a fast resurgence in the transplant activities post COVID
Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival
_256_384.png)
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
Subscribe To Our Newsletter & Stay Updated
